Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Hematology

Why Is the Polycythemia Vera Hematocrit Goal Below 45%?

At a Glance

In polycythemia vera, keeping hematocrit below 45% lowers the risk of major blood clots and cardiovascular events compared with allowing it to remain between 45% and 50%. A single reading just above 45% is not automatically an emergency, but follow your hematologist’s plan.

For patients with polycythemia vera (PV), evidence and medical guidelines generally recommend keeping your hematocrit below 45% [1][2]. This treatment target is based on clinical trials showing that maintaining hematocrit below this level helps reduce the risk of major blood clots and cardiovascular events [3]. While 45% is not a biological cliff where danger suddenly begins, keeping your hematocrit below this goal is an important part of managing your long-term health [4].

The Evidence: The CYTO-PV Trial

The recommendation to aim for less than 45% comes largely from a landmark clinical study called the CYTO-PV trial [3]. In this trial, researchers compared two groups of PV patients: one group had their hematocrit maintained below 45%, and the other group was maintained between 45% and 50% [3].

The trial found that patients in the under-45% group experienced fewer cardiovascular deaths and major thrombotic events (blood clots, such as heart attacks, strokes, and deep vein thrombosis) than those in the 45-50% group [4]. Large observational studies, such as the REVEAL study and Veterans Health Administration analyses, have also shown a population-level association: groups of patients whose hematocrit remained at or above 45% had a higher rate of blood clots over time compared to those consistently maintained below 45% [5][6]. However, these studies represent population averages, not a personal risk calculator for any individual patient.

What Happens When Hematocrit Rises?

Hematocrit is the percentage of your blood volume that is made up of red blood cells. When your body produces too many red blood cells, it physically changes how your blood behaves:

  • Increased Viscosity: As red blood cell mass increases, your blood becomes thicker (more viscous) [7].
  • Slower Blood Flow: The thicker blood moves more slowly, especially through the tiny blood vessels in your body known as the microcirculation [8][9].
  • Inflammation and Cell Activation: Thrombosis in PV is not just about having too many red blood cells. It is a complex process involving increased blood thickness combined with activated white blood cells, activated platelets, changes to the blood vessel lining, and overall inflammation [10][11].

This combination of thick, slow-moving blood and inflammation creates an environment where blood clots are more likely to form [12]. Poor circulation can also contribute to symptoms like headaches, temporary vision changes, or erythromelalgia (a severe burning pain and redness in the hands and feet) [8][13]. Note: These symptoms can have other causes, so it is important to discuss them with your doctor rather than assuming your hematocrit is too high.

Does a Reading of 45.5% Mean Immediate Danger?

A single hematocrit reading slightly above 45% does not mean a blood clot is forming at that exact moment. The 45% mark is a risk-management goal, not a sudden cliff [4]. Hematocrit levels can fluctuate based on hydration and other factors.

If your number creeps up to 45% or 46%, your care team will look at the trend over time, your current symptoms, and your other lab results before deciding what to do [1]. They may schedule a therapeutic phlebotomy (a medical procedure similar to donating blood that removes extra red blood cells) or adjust your cytoreductive medications (drugs like hydroxyurea or interferon that slow down blood cell production) [1].

Important: Do not self-adjust your medications, and do not use regular blood donation as a substitute for prescribed treatment. Always follow your hematologist’s specific action plan.

Emergency Symptoms vs. Routine Care

Because PV increases your risk for blood clots, it is critical to know when to seek immediate help.
Call 911 or go to an emergency room immediately if you experience signs of a serious clot, such as:

  • Sudden weakness or numbness, especially on one side of the face or body
  • Trouble speaking or understanding speech
  • Sudden vision loss
  • Chest pain or pressure
  • Sudden, severe shortness of breath or coughing up blood
  • Pain, swelling, or redness in one leg

For non-emergency symptoms like new or worsening headaches, burning in your hands or feet, or mild fatigue, contact your hematology team during regular hours for advice.

More Than Just Hematocrit: A Complete Risk Plan

Keeping your hematocrit under 45% is only one part of a complete risk-reduction plan. Your doctor will also consider:

  • Your Age and History: Being over age 60 or having a previous blood clot are major factors used to determine your overall risk and guide treatment [14][15].
  • Other Blood Counts: Elevated white blood cell counts (leukocytosis) and platelet counts are also monitored [6].
  • Low-Dose Aspirin: Many patients take low-dose aspirin to help prevent clots, but this is individualized. Do not start, stop, or change aspirin without your doctor’s advice due to bleeding risks [11].
  • Cardiovascular Risk Factors: Managing high blood pressure, high cholesterol, diabetes, and quitting smoking are essential parts of your PV care [11][16].

By understanding the “why” behind your blood count goals, you can work actively with your care team to protect your long-term health.

Common questions in this guide

Why is hematocrit kept below 45% in polycythemia vera?
In polycythemia vera, too many red blood cells can make blood thicker and increase clot risk. The CYTO-PV trial found fewer major clots and cardiovascular deaths when hematocrit was kept below 45% than when it was maintained at 45% to 50%.
Does a hematocrit of 45.5% mean I am in immediate danger?
Not necessarily. The 45% level is a treatment goal based on risk over time, not a point at which a clot suddenly forms, and hydration or normal variation can affect readings. Your hematology team will consider the trend, your symptoms, and other lab results before deciding what to do.
What might my doctor do if my PV hematocrit rises above 45%?
Your clinician may review the trend and schedule therapeutic phlebotomy, which removes extra red blood cells, or adjust a blood-cell-lowering medicine such as hydroxyurea or interferon. Do not change medication doses or use regular blood donation instead of prescribed treatment.
Which symptoms require emergency care when I have polycythemia vera?
Call 911 or go to an emergency room for sudden one-sided weakness or numbness, trouble speaking, sudden vision loss, chest pain, severe shortness of breath, coughing up blood, or a painful, swollen, or red leg. New or worsening headaches, burning in the hands or feet, or mild fatigue should be reported to your hematology team during regular hours unless they are severe or occur with emergency symptoms.
Is hematocrit the only blood test or risk factor that matters in PV?
No. Clinicians also consider white blood cell and platelet counts, age, previous clots, and cardiovascular risks such as high blood pressure, high cholesterol, diabetes, and smoking. Low-dose aspirin may be appropriate for some people, but it must be individualized because it can increase bleeding risk.
Can frequent phlebotomy cause iron deficiency in polycythemia vera?
Repeated phlebotomy can put some people at risk for iron deficiency, so your hematologist may decide whether iron testing is appropriate. Tell your care team about fatigue or other concerns rather than starting iron supplements on your own.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Are my current medications and phlebotomy schedule keeping my hematocrit consistently under the 45% target?
  2. 2.What is our action plan if my hematocrit creeps up into the 45-50% range between scheduled visits?
  3. 3.In addition to hematocrit, are my white blood cell and platelet counts in a safe range for my specific situation?
  4. 4.Is low-dose aspirin or another antiplatelet treatment appropriate for me, or do I have bleeding risks that make it unsafe?
  5. 5.How can we best manage my overall cardiovascular risk factors, such as blood pressure and cholesterol, alongside my PV treatment?
  6. 6.Am I at risk for iron deficiency from frequent phlebotomies, and should we test my iron levels?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Diagnosis and Treatment of Polycythemia Vera: A Review.

    Tremblay D, Kremyanskaya M, Mascarenhas J, Hoffman R

    JAMA 2025; (333(2)):153-160 doi:10.1001/jama.2024.20377.

    PMID: 39556352
  2. 2

    Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.

    Tefferi A, Barbui T

    American journal of hematology 2023; (98(9)):1465-1487 doi:10.1002/ajh.27002.

    PMID: 37357958
  3. 3

    Thromboembolic events in polycythemia vera.

    Griesshammer M, Kiladjian JJ, Besses C

    Annals of hematology 2019; (98(5)):1071-1082 doi:10.1007/s00277-019-03625-x.

    PMID: 30848334
  4. 4

    Myeloproliferative Neoplasms, Clonal Thrombosis, and Vascular Disease: Can Cardiology Learn from Hematology?

    Thukral J, Khangurra SK, Ghaie M, et al.

    Cardiology in review 2026; doi:10.1097/CRD.0000000000001285.

    PMID: 42059892
  5. 5

    Hematocrit levels and thrombotic events in patients with polycythemia vera: an analysis of Veterans Health Administration data.

    Parasuraman S, Yu J, Paranagama D, et al.

    Annals of hematology 2019; (98(11)):2533-2539 doi:10.1007/s00277-019-03793-w.

    PMID: 31552445
  6. 6

    Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL.

    Gerds AT, Mesa R, Burke JM, et al.

    Blood 2024; (143(16)):1646-1655 doi:10.1182/blood.2023020232.

    PMID: 38142448
  7. 7

    Red Blood Cell Contribution to Thrombosis in Polycythemia Vera and Essential Thrombocythemia.

    Grenier JMP, El Nemer W, De Grandis M

    International journal of molecular sciences 2024; (25(3)) doi:10.3390/ijms25031417.

    PMID: 38338695
  8. 8

    The effect of polycythemia vera on choroidal thickness and retrobulbar blood flow.

    Aydın N, Tufek M

    Photodiagnosis and photodynamic therapy 2024; (45()):103985 doi:10.1016/j.pdpdt.2024.103985.

    PMID: 38246214
  9. 9

    Polycythemia Vera-Associated Complications: Pathogenesis, Clinical Manifestations, And Effects On Outcomes.

    Cuthbert D, Stein BL

    Journal of blood medicine 2019; (10()):359-371 doi:10.2147/JBM.S189922.

    PMID: 31695542
  10. 10

    Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.

    Guy A, Mansier O, Decilap M, et al.

    Leukemia 2026; (40(2)):360-372 doi:10.1038/s41375-025-02836-8.

    PMID: 41436639
  11. 11

    Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera.

    Benevolo G, Marchetti M, Melchio R, et al.

    Vascular health and risk management 2023; (19()):765-778 doi:10.2147/VHRM.S429995.

    PMID: 38025519
  12. 12

    Intermittent retinal artery occlusions as the first clinical manifestation of polycythemia vera: a case report.

    Regensburger J, Rauchegger T, Loacker L, et al.

    BMC ophthalmology 2022; (22(1)):221 doi:10.1186/s12886-022-02423-w.

    PMID: 35570268
  13. 13

    Real-world treatments and thrombotic events in polycythemia vera patients in the USA.

    Verstovsek S, Pemmaraju N, Reaven NL, et al.

    Annals of hematology 2023; (102(3)):571-581 doi:10.1007/s00277-023-05089-6.

    PMID: 36637474
  14. 14

    Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients.

    Cerquozzi S, Barraco D, Lasho T, et al.

    Blood cancer journal 2017; (7(12)):662 doi:10.1038/s41408-017-0035-6.

    PMID: 29282357
  15. 15

    Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

    Barbui T, Tefferi A, Vannucchi AM, et al.

    Leukemia 2018; (32(5)):1057-1069 doi:10.1038/s41375-018-0077-1.

    PMID: 29515238
  16. 16

    Management of Polycythemia Vera: A Survey of Canadian Physician Practice Patterns.

    Habib LA, Kuo KHM, Panzarella T, et al.

    Clinical lymphoma, myeloma & leukemia 2019; (19(1)):e37-e42 doi:10.1016/j.clml.2018.07.297.

    PMID: 30322792

This page is for informational purposes only and does not constitute medical advice. It explains the usual PV hematocrit target; your hematologist should interpret your results and guide treatment, medication, aspirin, and phlebotomy decisions.

Get notified when new evidence is published on Polycythemia vera.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.